At the 24th Journées Européennes de la Société Française de Cardiologie from January 15th to 18th, 2014, the Professor Pathak talks about three main guidelines...
À l'occasion des 24èmes Journées Européennes de la Société Française de Cardiologie du 15 au 18 janvier 2014, le Pr Pathak revient sur les trois informations principales discutées en conférence...
Following the release of his new article in EuroIntervention Journal (January 2014), the first author Konstantinos Tsioufis talks about the renal denervation procedure.
Sebastian Ewen asks questions to Bernard Waeber, co-author of Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy...
Highlights on hypertension at the JESFC 2014
Le professeur Atul Pathak partage avec ses confrères francophones les principales recommandations de traitement de l'hypertension artérielle.
Sebastian Ewen asks questions to Bernard Waeber, co-author of Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy, article published in EuroIntervention Journal Supplement on Resistant Hypertension Treatments, May 2013.
Please share with us your comments about this renal denervation case, opening the path...
Please share with us your comments about this renal denervation case, opening the path for a new approach.
Discuss about the perspective of transradial denervation while following this case.
In light of Medtronic’s announcement of Thursday, 9th January 2014, about SYMPLICITY HTN-3, the Resistant Hypertension Course Scientific Board shares its point of view.
Medtronic, Inc. announced yesterday that its U.S. trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, has met its primary safety endpoint, while it did not reach its primary efficacy endpoint, defined as a difference of, at least, 15 mmHg office systolic blood pressure, between sham and active renal denervation groups.
The RHC Board shares its point of view: